Publication: Starting and Strengthening a National Pharmacovigilance System: The Case of Catalan Regional Activities that Propelled the Spanish Pharmacovigilance System
Loading...
Published
2023-08-15
ISSN
Date
2023-08-15
Author(s)
Editor(s)
Abstract
The Spanish System of Pharmacovigilance (SSPV) started its activities almost 40 years ago, in 1985. Of particular interest to others considering various options for developing pharmacovigilance systems is the fact that this case study highlights an example that built from the ground up and actually started in academia: the SSPV began as a research project in a university institution in Catalonia that was later adopted by the Ministry of Health. From these origins, a regulatory framework gradually allowed this initiative to expand to the whole country. In 1990, after technical training for the professional staff involved, responsibility for coordinating the system was transferred to a specially created coordinating center for the SSPV located in the Spanish Medicines Agency. This report reviews the origins of the system and its key features, followed by two examples of the system in action and closing comments on aspects and lessons that may be of particular value to others developing pharmacovigilance systems elsewhere.
Link to Data Set
Citation
“Wang, Huihui; Marquez, Patricio V.; Figueras, Albert; Bieliaieva, Kseniya. 2023. Starting and Strengthening a National Pharmacovigilance System: The Case of Catalan Regional Activities that Propelled the Spanish Pharmacovigilance System. Pharmacovigilance and Essential Public Health Services Series. © World Bank. http://hdl.handle.net/10986/40206 License: CC BY-NC 3.0 IGO.”
Digital Object Identifier
Associated URLs
Associated content
Other publications in this report series
Journal
Journal Volume
Journal Issue
Collections
Related items
Showing items related by metadata.
Publication The Value of Pharmacovigilance in Building Resilient Health Systems Post-COVID(World Bank, Washington, DC, 2023-08-15)Although indispensable for improving health outcomes, medicines and vaccines or their administration and use can produce adverse effects, requiring continuous vigilance to ensure that the benefits outweigh the risks. Monitoring the safety of the use of marketed medicines and vaccines, also known as pharmacovigilance, should therefore become much more explicit in efforts to strengthen health systems and prepare for public health crises and normal times because the world is determined to build back better after the COVID-19 pandemic. The objective of this report is to examine the importance of pharmacovigilance in a health system both during a health crisis and in normal times, describe the function, structure, and processes of a functional pharmacovigilance system, and explain the value of drug safety monitoring in building resilience in health systems post-COVID-19 pandemic.Publication Pharmacovigilance in Brazil(World Bank, Washington, DC, 2023-08-15)The ability to oversee and monitor the use of all newly authorized drugs and vaccines, both brand name and generic, is critical to ensure that they work correctly and that their health benefits outweigh their known risks when used in daily clinical practice. This process, known as pharmacovigilance, plays a vital role in ensuring that patients receive appropriate vaccines and medicines that are safe and effective. While this may seem obvious, the process of building the necessary capacity and even recognition of the importance of this work has taken decades. Brazil is a particularly notable example because it ranks in the top five amongst the largest and the most populated countries—two characteristics that difficult the deployment and consolidation of a pharmacovigilance system.Publication Realizing a Regional Approach to Pharmacovigilance(Washington, DC: World Bank, 2023-08-11)This report reviews the pharmacovigilance system of the European Union (EU) mapping out its structure and processes with any eye to features that may be of particular interest to decision makers in other regions as they weigh options related to creating a regional pharmacovigilance architecture for themselves. It begins with a review of the European Medicines Agency (EMA), which plays a central role in the EU system, followed by an overview of the EU PV assessment and monitoring process and an example of the system in action regarding COVID-19 vaccines. It concludes with a summary several key insights of particular relevance for decision makers.Publication Safety Monitoring of Medicines and Vaccines(World Bank, Washington, DC, 2023-08-15)Medicines, vaccines, medical devices, and blood are commonly used to treat disease. Medicines deserve a special focus because almost any medical visit ends with at least one prescription. So, monitoring the safety and effectiveness of therapeutic treatments and procedures is crucial at both the individual and community levels. In the case of medicines and vaccines, this surveillance activity is known as pharmacovigilance. Various methods are used to monitor the adverse and unwanted effects of medicinal products after they have received authorization for marketing, but reporting adverse reactions is the most widespread. The network of the Program for International Drug Monitoring (PIDM), which is supported by the World Health Organization (WHO), involves more than 170 countries. Its activities were initiated in 1968. The WHO-PIDM is the world’s most comprehensive network involving health professionals, patients, and manufacturers. This situation analysis describes relevant aspects of the PIDM, including achievements and weak points. The analysis is the product of a systematic revision of studies that focus on the WHO-PIDM activities and related findings published in different medical journals and listed in PubMed. Available information was selected and organized according to different topics and summarized and presented in the different sections of the report. As information for some countries and regions is lacking in the available literature, the report is not a comprehensive review of the pharmacovigilance across countries. The report, therefore, shows what is in place and highlight some of the difficulties faced by many countries, particularly low-and-middle income countries. It offers an overview of the (1) common points and failures; (2) the advantages of a national PV system; (3) the difficulties in scaling up and consolidating these systems; and (4) the advantages of regional collaboration. This report is part of a series of companion reports on pharmacovigilance, that provide a detailed overview and discussion on technical aspects and country and regional experiences.Publication The Caribbean Regulatory System(World Bank, Washington, DC, 2023-08-15)This report focuses on the Caribbean Public Health Agency (CARPHA), one of the three multi-national public health agencies in the world, that commenced operations on Jan 1, 2013, with the aim of delivering the functions of five previous regional health institutions through one platform for greater synergy and cost-effectiveness and as the principal institutional expression of Caribbean Cooperation in Health. The activities of CARPHA include the provision of a subregional mechanism that supports regulatory action to ensure access to safe medicines, such as the subregional system for reporting adverse drug reactions (ADRs) and substandard and falsified products (VigiCarib), and the regional post marketing drug quality testing program under the CARPHA Medicines Quality Control and Surveillance Department. Another relevant CARPHA activity is reviewing new medicines which want to enter the Caribbean market. This was especially important during the COVID-19 pandemic, with the plethora of new vaccines. VigiCarib is a good example of a subregional approach to facilitate well-functioning post marketing monitoring activities, including PV. Although this is a relatively new program, it is well established, integrates lessons from more experienced regulatory authorities, and supports small economies without specific PV programs, thus helping ensure the safety, quality, and effectiveness of medicines and vaccines. VigiCarib can serve as a model in other parts of the world where a regional approach to strengthening regulatory systems is under consideration. However, a key lesson of the experience of CARICOM, is that regional initiatives are complex and require clear objectives, harmonization, respect for the individual countries and territories, and mutual trust.
Users also downloaded
Showing related downloaded files
Publication Tailings Storage Facilities(World Bank, Washington, DC, 2021-04-22)Tailings storage facilities (TSFs) are engineered structures that comprise the confining embankments (commonly referred to as tailings dams) and associated works and are designed to contain tailings (residue following extraction of valuable material from metal ore processing) and to manage associated water. TSF contains mixed waste material from mining processes in liquid or slurry form and must be responsibly managed to prevent impacts on human health and safety, the environment, and other infrastructure. However, TSFs have historically suffered more problems than water storage dams. Internationally, TSFs have a historical long-term average of more than one major incident or failure per year. To manage mining facilities responsibly, the TSF owner must understand the physical and chemical risks associated with the TSF and implement controls to reduce risks relating to potential health, safety, environmental, societal, business, and economic impacts in line with regulations. International organizations, regulators and industries have developed guidelines to aid owners in the management of TSFs. These guidelines were used to develop this Technical Note. The Note is intended to raise awareness and inform specific studies/investigations, as appropriate, during project preparation.Publication Strategic Investment for Health System Resilience(Washington, DC: World Bank, 2024-08-26)As efforts to build emergency-ready health systems intensify across the globe, Strategic Investment for Health System Resilience: A Three-Layer Framework provides a practical investment framework and a diverse set of country cases to inform decision-making and strategic resource allocations. The framework includes layer 1, risk reduction—promoting emergency-ready primary health care, public health, prevention, and community preparedness; layer 2, detection, containment, and mitigation capabilities; and layer 3, advanced case management and surge response. This three-layer framework prioritizes interventions that prevent a public health threat from developing in the first place (layer 1), limit its spread should one emerge (layer 2), and manage a widespread crisis that compromises a health system’s ability to deliver care sustainably (layer 3). All three layers play a role in achieving health system resilience, but not all of them have been leveraged equally in the past. Strategic Investment for Health System Resilience offers a glimpse of the relatively low cost of investments in improving the operation of the weakest parts of the three layers. Layer 1 functions are estimated to cost between US$2 per capita in low-income countries and US$4 per capita in lower-middle-income countries. The framework applies equally to short-term epidemics of communicable diseases and to slow-moving trends in noncommunicable diseases. The pace of the needed response to health threats can vary, but all require a system that is resilient across multiple layers of response. Although there is no universal blueprint for every setting, it behooves all countries to seize the moment and invest in the three layers in ways that fit their needs.Publication Digital Africa(Washington, DC: World Bank, 2023-03-13)All African countries need better and more jobs for their growing populations. "Digital Africa: Technological Transformation for Jobs" shows that broader use of productivity-enhancing, digital technologies by enterprises and households is imperative to generate such jobs, including for lower-skilled people. At the same time, it can support not only countries’ short-term objective of postpandemic economic recovery but also their vision of economic transformation with more inclusive growth. These outcomes are not automatic, however. Mobile internet availability has increased throughout the continent in recent years, but Africa’s uptake gap is the highest in the world. Areas with at least 3G mobile internet service now cover 84 percent of Africa’s population, but only 22 percent uses such services. And the average African business lags in the use of smartphones and computers as well as more sophisticated digital technologies that catalyze further productivity gains. Two issues explain the usage gap: affordability of these new technologies and willingness to use them. For the 40 percent of Africans below the extreme poverty line, mobile data plans alone would cost one-third of their incomes—in addition to the price of access devices, apps, and electricity. Data plans for small- and medium-size businesses are also more expensive than in other regions. Moreover, shortcomings in the quality of internet services—and in the supply of attractive, skills-appropriate apps that promote entrepreneurship and raise earnings—dampen people’s willingness to use them. For those countries already using these technologies, the development payoffs are significant. New empirical studies for this report add to the rapidly growing evidence that mobile internet availability directly raises enterprise productivity, increases jobs, and reduces poverty throughout Africa. To realize these and other benefits more widely, Africa’s countries must implement complementary and mutually reinforcing policies to strengthen both consumers’ ability to pay and willingness to use digital technologies. These interventions must prioritize productive use to generate large numbers of inclusive jobs in a region poised to benefit from a massive, youthful workforce—one projected to become the world’s largest by the end of this century.Publication Increasing Female Labor Force Participation(World Bank, Washington, DC, 2023-01)Gender gaps in labor force participation persist worldwide. Closing this gap can lead to sizeable gains for economies—a 20 percent increase in GDP per capita, on average. Female labor force participation (FLFP) remains low due to lack of skills, assets and networks, time-based constraints, limited mobility, gender discrimination in hiring and promotion, and restrictive gender norms. Effective evidence-backed policy options can increase FLFP. They include providing childcare services, disseminating information on work opportunities and returns to employment, training in socio-emotional skills, addressing norms by engaging partners and family members, and targeting women via social protection, safety net, and public-works programs. The World Bank Group actively supports countries in boosting FLFP through development policy lending, advisory and analytical work, and supporting reforms to address constraining contextual factors, including legal barriers, social norms, and gender-based violence. This note sheds light on an array of policy options that are effective or show promise in improving FLFP.Publication The Frontline Scorecard(Washington, DC: World Bank, 2024-04-03)Health care systems are at the frontline of delivering critical care during emergencies, mitigating illnesses and deaths. Yet many countries struggle to meet even routine demands for health care. Climate change, disasters, pandemics, and demographic changes are bound to increase pressures on already strained health systems (Rentschler et al. 2021). Preparing and equipping health systems to adequately respond to crises are vital to ensure sustained access to health services and to provide reliable essential health care that protects people’s well-being. Having a robust assessment of their country’s health system’s climate and disaster risk management (CDRM) capabilities allows policy makers to make these systems more resilient against shocks. This policy note introduces the Frontline Scorecard, a new rapid diagnostic tool that decision makers can use to conduct a high-level assessment of the CDRM capabilities of their health system, and illustrates its application in a case-study country, Belize.